Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ELVN |
---|---|---|
09:32 ET | 2824 | 25.19 |
09:41 ET | 100 | 25.655 |
09:43 ET | 100 | 25.72 |
09:52 ET | 1670 | 25.96 |
09:54 ET | 500 | 25.995 |
09:56 ET | 465 | 26.2 |
09:59 ET | 800 | 25.79 |
10:01 ET | 100 | 26.19 |
10:06 ET | 100 | 26.12 |
10:08 ET | 100 | 26.19 |
10:10 ET | 1600 | 25.915 |
10:12 ET | 1502 | 25.66 |
10:14 ET | 1300 | 25.525 |
10:19 ET | 3213 | 25.5 |
10:21 ET | 400 | 25.555 |
10:24 ET | 300 | 25.55 |
10:26 ET | 200 | 25.55 |
10:28 ET | 19800 | 25.66 |
10:30 ET | 1000 | 25.44 |
10:32 ET | 800 | 25.425 |
10:33 ET | 100 | 25.425 |
10:35 ET | 200 | 25.54 |
10:37 ET | 100 | 25.54 |
10:39 ET | 721 | 25.55 |
10:42 ET | 400 | 25.7 |
10:44 ET | 300 | 25.85 |
10:46 ET | 300 | 26.02 |
10:48 ET | 400 | 25.99 |
10:50 ET | 300 | 26.04 |
10:51 ET | 100 | 26.07 |
10:53 ET | 300 | 26.06 |
10:55 ET | 300 | 26.07 |
10:57 ET | 300 | 26.05 |
11:00 ET | 500 | 26.18 |
11:02 ET | 100 | 25.905 |
11:04 ET | 100 | 25.91 |
11:06 ET | 300 | 25.9135 |
11:15 ET | 1500 | 25.805 |
11:26 ET | 257 | 25.83 |
11:31 ET | 200 | 25.89 |
11:45 ET | 300 | 25.82 |
11:49 ET | 100 | 25.82 |
11:51 ET | 1000 | 25.82 |
11:56 ET | 415 | 25.77 |
12:03 ET | 1400 | 25.895 |
12:05 ET | 100 | 25.895 |
12:07 ET | 200 | 25.9 |
12:09 ET | 1700 | 25.89 |
12:20 ET | 300 | 25.73 |
12:30 ET | 100 | 25.665 |
12:38 ET | 100 | 25.59 |
12:39 ET | 100 | 25.73 |
12:43 ET | 100 | 25.73 |
12:48 ET | 138 | 25.69 |
12:50 ET | 400 | 25.6 |
12:52 ET | 100 | 25.64 |
01:01 ET | 207 | 25.5813 |
01:06 ET | 300 | 25.82 |
01:19 ET | 100 | 25.89 |
01:26 ET | 200 | 25.83 |
01:28 ET | 825 | 25.89 |
01:30 ET | 266 | 25.96 |
01:32 ET | 899 | 25.91 |
01:35 ET | 500 | 25.84 |
01:46 ET | 700 | 25.98 |
01:48 ET | 2436 | 26 |
01:51 ET | 300 | 26.095 |
01:57 ET | 100 | 26.16 |
02:04 ET | 488 | 26.17 |
02:11 ET | 1509 | 26.39 |
02:13 ET | 100 | 26.48 |
02:22 ET | 100 | 26.485 |
02:26 ET | 100 | 26.58 |
02:33 ET | 659 | 26.4 |
02:38 ET | 100 | 26.38 |
02:42 ET | 533 | 26.43 |
02:44 ET | 1706 | 26.52 |
02:45 ET | 200 | 26.56 |
02:51 ET | 100 | 26.56 |
02:54 ET | 100 | 26.64 |
02:58 ET | 100 | 26.64 |
03:00 ET | 400 | 26.5 |
03:02 ET | 508 | 26.46 |
03:03 ET | 100 | 26.42 |
03:05 ET | 1720 | 26.43 |
03:07 ET | 100 | 26.475 |
03:09 ET | 100 | 26.535 |
03:12 ET | 200 | 26.55 |
03:14 ET | 750 | 26.55 |
03:16 ET | 100 | 26.55 |
03:20 ET | 100 | 26.57 |
03:21 ET | 300 | 26.639 |
03:23 ET | 1490 | 26.74 |
03:25 ET | 4284 | 26.97 |
03:27 ET | 3300 | 27.31 |
03:30 ET | 600 | 27.03 |
03:32 ET | 500 | 26.95 |
03:34 ET | 200 | 27.03 |
03:38 ET | 500 | 27.03 |
03:39 ET | 100 | 27.03 |
03:41 ET | 600 | 27.03 |
03:43 ET | 500 | 26.91 |
03:45 ET | 821 | 27.1 |
03:48 ET | 1778 | 27.045 |
03:50 ET | 1140 | 27.16 |
03:52 ET | 5472 | 27.3 |
03:54 ET | 900 | 27.355 |
03:56 ET | 4500 | 27.42 |
03:57 ET | 3321 | 27.405 |
03:59 ET | 8936 | 27.31 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Enliven Therapeutics Inc | 1.2B | -14.2x | --- |
Cullinan Therapeutics Inc | 1.1B | -6.4x | --- |
Autolus Therapeutics PLC | 1.2B | -3.9x | --- |
Centessa Pharmaceuticals PLC | 1.2B | -7.6x | --- |
ARS Pharmaceuticals Inc | 1.1B | -21.1x | --- |
Tyra Biosciences Inc | 1.1B | -11.9x | --- |
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 47.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-1.93 |
Book Value | $5.95 |
P/E Ratio | -14.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.